Hot Space: PE Advent Snaps Up Second API Manufacturer In India
More Buyers Than Sellers In Sector?
Private equity investor Advent has acquired API maker ZCL Chemicals in India, its second transaction in a segment seeing rising interest as pharma de-risks sourcing for key ingredients post COVID-19-related turbulence.
You may also be interested in...
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.